OCULAR THERAPEUTIX Files 8-K for Routine Administrative Update
Ticker: OCUL · Form: 8-K · Filed: Jan 25, 2024 · CIK: 1393434
| Field | Detail |
|---|---|
| Company | Ocular Therapeutix, Inc (OCUL) |
| Form Type | 8-K |
| Filed Date | Jan 25, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, compliance, 8-K
TL;DR
**OCUL filed a routine 8-K, no major news.**
AI Summary
OCULAR THERAPEUTIX, INC. filed an 8-K on January 25, 2024, to report an "Other Event." This filing primarily serves to update administrative information, such as the company's current address at 24 Crosby Drive, Bedford, MA 01730, and its telephone number, (781) 357-4000. For investors, this filing indicates routine compliance and no significant operational or financial changes, meaning there's no immediate impact on the stock's value based on this specific report.
Why It Matters
This filing is a standard administrative update, indicating routine compliance with SEC regulations rather than a material event impacting the company's operations or financial health.
Risk Assessment
Risk Level: low — This 8-K filing reports an 'Other Event' which appears to be purely administrative, posing no direct financial or operational risk to the company or its investors.
Analyst Insight
Investors should note this is a routine administrative filing and does not contain new information that would typically influence investment decisions. No immediate action is warranted based on this specific report.
Key Players & Entities
- OCULAR THERAPEUTIX, INC. (company) — the registrant filing the 8-K
- January 25, 2024 (date) — date of earliest event reported and filing date
- 24 Crosby Drive, Bedford, MA 01730 (other) — principal executive offices address
- (781) 357-4000 (other) — company's telephone number
- 001-36554 (other) — Commission File Number
- OCUL (other) — Trading Symbol on The Nasdaq Global Market
FAQ
What is the purpose of this specific 8-K filing by OCULAR THERAPEUTIX, INC.?
This 8-K filing, dated January 25, 2024, is categorized under 'Other Events' and primarily serves to update administrative information, such as the company's current address and telephone number, and confirm its registration details with the SEC.
What is the current business address and phone number of OCULAR THERAPEUTIX, INC. as reported in this filing?
According to the filing, the company's principal executive offices are located at 24 Crosby Drive, Bedford, MA 01730, and its telephone number is (781) 357-4000.
On what date was the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is January 25, 2024.
What is the trading symbol and the exchange on which OCULAR THERAPEUTIX, INC.'s common stock is registered?
The common stock of OCULAR THERAPEUTIX, INC. trades under the symbol 'OCUL' on The Nasdaq Global Market.
Does this 8-K filing indicate any significant financial or operational changes for OCULAR THERAPEUTIX, INC.?
No, this 8-K filing does not indicate any significant financial or operational changes. It is a routine administrative update under 'Other Events' and does not contain information about mergers, acquisitions, earnings, or other material business developments.
Filing Stats: 1,096 words · 4 min read · ~4 pages · Grade level 18.5 · Accepted 2024-01-25 08:04:32
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share OCUL The Nasdaq
Filing Documents
- tm244106d1_8k.htm (8-K) — 26KB
- 0001104659-24-006490.txt ( ) — 194KB
- ocul-20240125.xsd (EX-101.SCH) — 3KB
- ocul-20240125_lab.xml (EX-101.LAB) — 33KB
- ocul-20240125_pre.xml (EX-101.PRE) — 22KB
- tm244106d1_8k_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On January 25, 2024, Ocular Therapeutix, Inc. (the "Company") announced that the U.S. Food and Drug Administration (the "FDA") had agreed to a Special Protocol Assessment ("SPA") Agreement Modification for the Company's pivotal Phase 3 clinical trial (the "SOL trial") evaluating AXPAXLI (axitinib intravitreal implant) for the treatment of wet age-related macular degeneration ("wet AMD"). The SPA Agreement Modification enables the SOL trial to include treatment nave wet AMD subjects with visual acuity of approximately 20/80 or better at the initial screening visit. After two aflibercept injections in the screening period, eligible participants would need to gain at least 10 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters from the initial screening visit to Day 1 or achieve a visual acuity of approximately 20/20 or better at Day 1, in addition to satisfying other criteria, to qualify for enrollment in the SOL trial. The SPA Agreement Modification also allows the SOL trial to evaluate a single optimized implant of AXPAXLI with a drug load of 450 g of a more soluble form of axitinib. This optimized configuration is expected to provide for a slightly increased daily release of the drug and is designed to improve synchronization of axitinib drug depletion with hydrogel bioresorption. Cautionary Note on Forward Looking Statements Any statements in this Current Report on Form 8-K about future expectations, plans, and prospects for the Company, including the development and regulatory status of the Company's product candidates, including the timing, design, and enrollment of the Company's pivotal trials of AXPAXLI (also called OTX-TKI) for the treatment of wet AMD; the Company's plans to advance the development of AXPAXLI; and other statements containing the words anticipate, believe, estimate, expect, intend, goal, may, might, plan, predict, project, target, potential, will, would, could, should, continue, and similar expressions
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OCULAR THERAPEUTIX, INC. Date: January 25, 2024 By: /s/ Donald Notman Donald Notman Chief Financial Officer